If you are researching a Zostavax shingles-vaccine claim, the honest status matters: the core cases alleging the vaccine caused shingles were dismissed and lost on appeal, and only a narrower set of injury claims remains. Here is where MDL 2848 actually stands.
Allegations Only · Core Cases Dismissed
This page describes litigation and its outcomes. The injury claims described below are unproven allegations, and Merck has not been found liable in any Zostavax trial. The cases alleging the vaccine caused shingles were dismissed, and that dismissal was affirmed on appeal. There is no class action, no settlement, and nothing to claim on this page. This is informational and is not legal or medical advice, and nothing here is a recommendation for or against any vaccine — discuss vaccination with your doctor.
What Is This About?
Zostavax is a live-virus shingles vaccine made by Merck. It was widely used in the United States until the newer, non-live vaccine Shingrix largely replaced it. Beginning around 2018, thousands of people who received Zostavax filed lawsuits alleging the vaccine had injured them.The federal cases were consolidated in multidistrict litigation known as MDL 2848, In re: Zostavax (Zoster Vaccine Live) Products Liability Litigation, before Judge Harvey Bartle III in the U.S. District Court for the Eastern District of Pennsylvania. These are individual injury cases coordinated for pretrial handling; there is no class action.
Anyone researching this litigation should understand its current posture clearly: the central theory — that Zostavax caused the plaintiff's shingles — was rejected by the court on scientific-proof grounds and the dismissals were upheld on appeal. What remains is a smaller, harder set of claims about other alleged injuries.
What the Lawsuits Alleged
Plaintiffs alleged that Zostavax caused a range of injuries and that Merck failed to adequately warn about them. The largest group alleged that the live vaccine actually triggered the very condition it was designed to prevent — a case of shingles. Other plaintiffs alleged non-shingles injuries, including autoimmune reactions, neurological injuries such as Guillain-Barre syndrome and peripheral neuropathy, hearing loss, eye injuries, and, in some cases, death.To manage the cases, the court divided them into groups — most importantly a "Group A" of plaintiffs alleging the vaccine caused their shingles, and other groups alleging non-shingles injuries. That division set up the pivotal ruling in the litigation.
The Lone Pine Order & the Group A Dismissals
The problem for the shingles-causation cases was one of proof. A live shingles vaccine uses a weakened "Oka" strain of the varicella-zoster virus — the same family of virus that causes natural chickenpox and shingles. To show that a plaintiff's shingles came from the vaccine rather than from a natural reactivation of the virus, you generally need a PCR laboratory test that identifies the specific viral strain.In March 2022, Judge Bartle entered what is known as a Lone Pine order, requiring each Group A plaintiff to produce PCR test results showing the vaccine's Oka strain caused their shingles. The court reasoned that PCR strain-typing was the only scientifically reliable way to tell vaccine-strain shingles apart from ordinary shingles. Because doctors rarely run that test during a shingles episode — and it generally cannot be obtained after the fact — most Group A plaintiffs could not comply. In December 2022, the court dismissed roughly 1,189 Group A cases with prejudice for failing to meet the order.
The plaintiffs appealed, and on July 16, 2024, the U.S. Court of Appeals for the Third Circuit affirmed the Lone Pine order and the resulting dismissals. That decision effectively ended the shingles-causation theory in the federal litigation.
What Remains — and Why It Is Hard
After the Group A dismissals, what remains in MDL 2848 is a smaller pool of cases — roughly 826 actions as of July 1, 2026 — alleging non-shingles injuries such as hearing loss, autoimmune conditions, and neurological injuries. These cases face their own causation hurdles. The court has, in some instances, accepted that plaintiffs' experts could speak to general causation while still excluding specific-causation opinions that failed to rule out other explanations, leading to further individual dismissals. No Zostavax case has been tried to a verdict.The practical bottom line: this is a litigation in retreat, not an open claims opportunity. There is no class action, no settlement, and no claim form. Anyone who believes they were seriously injured by a vaccine should speak with a physician and, if they wish, a qualified attorney about whether any individual avenue remains — but they should not expect a settlement program on these facts.
Frequently Asked Questions
What did the Zostavax lawsuits allege?
Plaintiffs alleged that Merck's Zostavax — a live-virus shingles vaccine — caused injuries, including a claim that it triggered the very shingles it was meant to prevent, as well as autoimmune reactions, neurological injuries such as Guillain-Barre syndrome, hearing loss, eye injuries, and, in some cases, death. These were allegations; no Zostavax case has been tried to a verdict.
Why were so many Zostavax cases dismissed?
The cases alleging the vaccine caused shingles (Group A) were dismissed under a Lone Pine order. In 2022 the court required each of those plaintiffs to produce a PCR lab test showing their shingles was caused by the vaccine's Oka strain rather than a natural infection. The court found PCR testing was the only reliable way to tell the two apart, and most plaintiffs could not produce it, so about 1,189 Group A cases were dismissed with prejudice in December 2022. The Third Circuit affirmed that outcome in July 2024.
Is there a Zostavax settlement?
No. There is no class action and no global settlement, and no Zostavax case has been settled or tried. The shingles-causation cases were dismissed and that dismissal was affirmed on appeal. A smaller group of cases alleging non-shingles injuries remains pending in MDL 2848, but there is nothing to claim on this page.
What cases are still pending in the Zostavax MDL?
After the shingles-causation cases were dismissed, what remains are roughly 826 actions (as of July 1, 2026) alleging non-shingles injuries — for example hearing loss, autoimmune reactions, and neurological injuries such as Guillain-Barre syndrome. These cases continue to face individual causation challenges before Judge Harvey Bartle III in the Eastern District of Pennsylvania.
Related Mass Torts & Sources
• Fosamax atypical femur fracture lawsuit (MDL 2243) — another Merck pharmaceutical MDL, recently revived on appeal.• PPI kidney injury lawsuit (MDL 2789) — a drug MDL that resolved through settlements.
• Dupixent lymphoma lawsuit (MDL 3180) — a newer drug MDL where causation is still unproven.
Primary sources: the U.S. Court of Appeals for the Third Circuit's July 16, 2024 opinion affirming the Lone Pine dismissals (No. 23-1032); the U.S. District Court for the Eastern District of Pennsylvania MDL 2848 docket and pretrial orders; and the U.S. Judicial Panel on Multidistrict Litigation (JPML) pending-MDL statistics.
Important Disclosures
This page is for general informational purposes and does not constitute medical or legal advice, and it is not a recommendation for or against any vaccine. You should consult a qualified attorney about your individual situation and your doctor about your health. OpenClassActions.com is not a law firm and is not a claims administrator, and this page does not create an attorney-client relationship.Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
